



## New study data shows prior osteoporotic fractures put women at increased risk of future major osteoporotic fractures

- Risk of a subsequent fracture was highest within the first two years after the previous fracture according to Swedish observational study<sup>1</sup>
- Prior vertebral fracture led to a higher risk of subsequent fracture compared to prior hip or any other fragility fracture<sup>1</sup>

**BRUSSELS, Belgium (8<sup>th</sup> November, 2017)** – UCB (Euronext Brussels: UCB) today presented results from a retrospective Swedish observational cohort study that assessed the risk of subsequent major osteoporotic fracture over time for women experiencing their first, second and third fragility fractures. The analysis found that the risk of subsequent fracture was highest within the first two years after the previous fracture compared to non-fracture controls.<sup>1</sup> This analysis, performed by Quantify Research and funded by UCB, was presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, Glasgow, UK.

“These data show that for individuals who have previously experienced a fracture due to osteoporosis, they are at higher risk of subsequent fracture, particularly in the first few months post-fracture,” said Professor Kristina Åkesson, Department of Orthopedics, Skane University Hospital, Lund University, Malmö, Sweden. “The personal, social and medical cost of a fracture cannot be overstated and these results serve as an important reminder that a fracture should be seen as a warning sign and early diagnosis and treatment of osteoporosis should be prioritised to prevent future fractures.”

The study used data collected from 229,259 women from Swedish national registers between 1998 and 2015. Women aged >49 and who had sustained one, two or three fragility fractures between 2006 and 2012 were included in the study. The study aimed to estimate the risk of subsequent major osteoporotic fracture over time for women experiencing their first, second or third fragility fracture (hip, vertebral, radius, humerus) compared with non-fracture controls. After controlling for various baseline characteristics such as age, dependency and glucocorticoid use, there remained an increased risk in women with multiple fractures compared with non-fracture controls.<sup>1</sup> Women who had sustained two prior fractures had a higher risk than those with only one prior fracture; the cumulative 1, 2 and 5-year incidence of the second major osteoporotic fracture in patients was 6%, 12% and 25%, respectively, and for a third subsequent fracture this was 10%, 19% and 40%, respectively.<sup>1</sup>

In addition, the analysis showed that fracture type influenced future fracture risk. Vertebral fractures were found to be more indicative of future fracture risk.<sup>1</sup>

“Preventing fragility fractures must become a public health priority. Fractures lead to further fractures, but despite this, 80% of patients who break a bone are not adequately managed for osteoporosis. By not responding to the warning sign of a first fracture, we risk failing to prevent the second and subsequent fractures,” said Dr. Pascale Richetta, Head of Bone and Executive Vice President at UCB. “At UCB we are working to increase awareness among patients and healthcare professionals of the risks associated with fragility fractures, and why it’s important to diagnosis and treat osteoporosis. More focus should also be given to Fracture Liaison Services: they are an effective post-fracture care model, relieving pressure from healthcare systems and resulting in fewer fractures and therefore a better quality of life for the persons concerned.”

**References**

1. Jonsson E, Ström O, Spångéus A, et al. Risk of major osteoporotic fracture (hip, vertebral, radius, humerus [mof]) after first, second and third fragility fracture in a Swedish general population cohort. Presented at IPSOR 2017, Poster # PMS13.

**About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7,500 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news

**UCB Forward-Looking Statements**

*This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.*

*Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this presentation and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.*

*There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.*

*Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.*

**For further information**

Scott Fleming, Global Communications Lead, Bone, UCB  
T: +447702777378, E: [scott.fleming@ucb.com](mailto:scott.fleming@ucb.com)